A research and development Blueprint for action to prevent epidemics
A Guide to Sharing the Data and Benefits of Public Health Surveillance
Sharing public health surveillance data enables regional collaborations, capacity strengthening and insight into public health system performance, leads to overall improvements in risk management, and enhances public health responsiveness. The Guide, developed as part of the Chatham House Centre on Global Health Security project, is intended to facilitate both informal and formal data sharing, and to be used when a need to share public health surveillance data has been identified or when obstacles to sharing have been encountered. It aims to help create the right environment for data sharing, to facilitate good practice in addressing technical, political, ethical, economic and legal concerns.
Sharing biological samples and data during public health emergencies
WHO is developing a web-based Material Transfer Agreement (MTA) tool to facilitate discussions between parties and ensure that all those involved with negotiating the movement of samples are empowered to protect their interests. This document under development discusses in detail the possible approaches that can be used to share samples and benefits on the same footing, and provides concrete, real world examples of how these can be embedded in an MTA. WHO will finalise the Material Transfer Agreement capacity building tool, after taking into account comments received. The online consultation closes on 16 June. WHO will finalise the Material Transfer Agreement capacity building tool, after taking into account comments received.
WHO Publishes MERS-CoV Vaccine Product Profile
As of May 2017, WHO has been notified of more than 1,950 laboratory confirmed cases of infection and at least 693 deaths related to MERS-CoV. WHO has developed a set of MERS-CoV vaccine Target Product Profiles following the strategies outlined in the MERS-CoV roadmap led by WHO and developed with key stakeholders. The TPPs are for 1 animal vaccine (for prevention of transmission from dromedary camels to humans) and 2 human vaccines (for reactive use in outbreak settings and for long term protection of high risk groups). The final document is made available here, after comments from a public consultation were considered. This is a living document, which may be updated in future as new information becomes available.
Public consultation on preferred profile for epidemic vaccine manufacturing platforms
Manufacturing platforms are needed to support development of vaccines in the event of an epidemic. The R&D Blueprint aims to provide preferred characteristics for such platforms to support funders and industry groups in making well informed decisions. WHO is seeking comments on the document below, which was developed by the CEPI secretariat and is shared with their consent. Comments may be submitted by individuals or organizations through the form attached below and sent to email@example.com – with name and affiliation. Deadline is COB 20 May 2017. Note that all comments may be made publicly available at a later stage. WHO will publish the finalized preferred profile for epidemic vaccine manufacturing platforms after taking into account comments received.
Public consultation on target product profile for Lassa Fever vaccine
Lassa Fever is a disease in the WHO R&D Blueprint list of epidemic threats needing urgent R&D action. WHO has just published a draft Lassa Fever vaccine target product profile for preventive use, which is now available for public consultation. Comments may be submitted by individuals or organizations through the form attached below and sent to firstname.lastname@example.org – with name and affiliation. Deadline is COB 2 May 2017 Note that all comments may be made publicly available at a later stage. WHO will publish the finalized Lassa Fever target product profile after taking into account comments received.
About R&D Blueprint
- Public consultation on Draft R&D Blueprint MTA Tool
- Sharing biological samples and data
140th Executive Board Report
Long Report of the prioritization of pathogens meeting 2017
ICDRA identifies regulatory gaps during emergencies